KIFIK Medical is a subsidiary of Centaur Clinical (a CRO focusing on Medical Devices). KIFIK owns the patent of the class 2 implantable device (FDA, class 3 in EU), called Swellness. KIFIK was created back in 2019 and is currently seeking to raise funding for the pivotal and early commercial stage of the product. All the preclinical assays were performed and a pilot study is about to start (project Q1 2024, submission ongoing to the regulatory authorities in France).